Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your Number one method for praising a birthday - 2Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- 3Struggling to keep your New Year's resolutions? Here's how to keep yourself on track
- 4Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- 5Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- Volkswagen in talks with defence firms on use of Germany plant: CEO
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Thorough Aide
- India’s delayed climate plan sets modest emission target
- Online business Stages for Little Retailers
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Artemis 2 astronauts reveal adorable zero-g indicator 'Rise' | Space photo of the day for March 31, 2026
- Father and son spending Christmas together after health scares
